DR Reddy S Laboratories Limited — Bevacizumab Exporter Profile
Indian Pharmaceutical Exporter · #8 for Bevacizumab · $8.0M export value · DGFT Verified
DR Reddy S Laboratories Limited is the #8 Indian exporter of Bevacizumab with $8.0M in export value and 10 verified shipments. DR Reddy S Laboratories Limited holds a 1.5% market share in Bevacizumab exports across 4 countries. The company exports 50 pharmaceutical products worth $310.6M across 19 therapeutic categories.
DR Reddy S Laboratories Limited — Bevacizumab Export Profile: Buyers & Destinations
Where Does DR Reddy S Laboratories Limited Export Bevacizumab?
| Country | Value | Shipments | Share |
|---|---|---|---|
| RUSSIA | $2.6M | 52 | 51.0% |
| COLOMBIA | $1.3M | 29 | 26.9% |
| THAILAND | $294.4K | 12 | 5.9% |
| MALDIVES | $274.5K | 10 | 5.5% |
| SOUTH AFRICA | $144.5K | 5 | 2.9% |
| UNITED KINGDOM | $111.3K | 6 | 2.2% |
| KENYA | $86.9K | 2 | 1.7% |
| POLAND | $82.5K | 5 | 1.7% |
| MAURITIUS | $63.2K | 3 | 1.3% |
| ALGERIA | $16.3K | 5 | 0.3% |
DR Reddy S Laboratories Limited exports Bevacizumab to 15 countries. The largest destination is RUSSIA accounting for 51.0% of DR Reddy S Laboratories Limited's Bevacizumab shipments, followed by COLOMBIA (26.9%) and THAILAND (5.9%). These destinations reflect DR Reddy S Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Bevacizumab from DR Reddy S Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| JSC R-PHARM | RUSSIA | $2.5M | 51 |
| DR.REDDYS LABORATORIES SAS | COLOMBIA | $937.1K | 20 |
| DR. REDDYS LABORATORIES SAS | COLOMBIA | $408.2K | 9 |
| STATE TRADING ORGANIZATION PLC | MALDIVES | $115.6K | 5 |
| MOVIANTO UK LIMITED | UNITED KINGDOM | $111.3K | 6 |
| STATE TRADING ORGANIZATION PLC. | MALDIVES | $108.9K | 4 |
| DR.REDDYS LABORATORIES(PTY)LTD, | SOUTH AFRICA | $100.0K | 2 |
| DR. REDDY'S LABORATORIES (THAILAND) | THAILAND | $88.1K | 3 |
| DR. REDDYS LABORATORIES (THAILAND) | THAILAND | $83.9K | 3 |
| SELVTIA SERVICES SP.Z O.O. | POLAND | $82.5K | 5 |
DR Reddy S Laboratories Limited supplies Bevacizumab to 26 buyers globally. The largest buyer is JSC R-PHARM (RUSSIA), followed by DR.REDDYS LABORATORIES SAS (COLOMBIA) and DR. REDDYS LABORATORIES SAS (COLOMBIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Bevacizumab Export Value and How Much Does DR Reddy S Laboratories Limited Contribute?
India exported $15.2M worth of Bevacizumab through 1,408 shipments from 196 suppliers to 100 countries, serving 346 buyers globally. DR Reddy S Laboratories Limited contributes $8.0M to this total, accounting for 1.5% of India's Bevacizumab exports. DR Reddy S Laboratories Limited ships Bevacizumab to 15 countries through 26 buyers.
What Is the Average Shipment Value for DR Reddy S Laboratories Limited's Bevacizumab Exports?
DR Reddy S Laboratories Limited's average Bevacizumab shipment value is $800.0K per consignment, based on 10 shipments totaling $8.0M. The largest destination is RUSSIA (51.0% of DR Reddy S Laboratories Limited's Bevacizumab exports).
How Does DR Reddy S Laboratories Limited Compare to Other Indian Bevacizumab Exporters?
DR Reddy S Laboratories Limited ranks #8 among 196 Indian Bevacizumab exporters with a 1.5% market share. The top 3 exporters are DR.REDDY'S LABORATORIES LTD ($6.5M), BIOCON BIOLOGICS INDIA LIMITED ($2.3M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($2.1M). DR Reddy S Laboratories Limited processed 10 shipments to 4 destination countries.
What Bevacizumab Formulations Does DR Reddy S Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION CO | $1.1M | 22 |
| PERSIVIA 100MG/4ML(BEVACIZUMAB(1S))(QTY: | $250.0K | 5 |
| PERSIVIA 100MG/4ML(BEVACIZUMAB)[1S](QTY: | $150.0K | 3 |
| VERSAVO 100MG (BEVACIZUMAB) | $122.5K | 5 |
| BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION CONCENTRATION 34.0 MG/ML WITH BUFFER SOLUTION 28,404 L(QTY:965.736 GMS) | $100.0K | 2 |
| BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION CONCENTRATION 36.0 MG/ML WITH BUFFER SOLUTION 28,040 L(QTY:1009.440 GMS) | $100.0K | 2 |
| VERSAVO 100MG (BEVACIZUMAB)VLS | $62.7K | 2 |
| VERSAVO 100MG(BEVACIZUMAB)(QTY:1000 VIALS) | $59.5K | 2 |
| PERSIVIA 100MG/4ML 1S (BEVACIZUMAB)(QTY:1011 VIALS)VLS | $50.0K | 1 |
| PERSIVIA 100MG/4ML (1S) (BEVACIZUMAB)(QTY:770 VIALS)VLS | $50.0K | 1 |
DR Reddy S Laboratories Limited exports 103 distinct Bevacizumab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION CO with 22 shipments worth $1.1M.
How Does DR Reddy S Laboratories Limited Compare to Nearest Bevacizumab Exporters?
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | MYLAN PHARMACEUTICALS PRIVATE LIMITED | $650.0K | 13 | 5 | $50.0K |
| 6 | DR REDDYS LABORATORIES LIMITED | $500.0K | 10 | 4 | $50.0K |
| 8 | DR.REDDY'S LABORATORIES LIMITED ★ | $500.0K | 10 | 4 | $50.0K |
| 10 | DR REDDY S LABORATORIES LIMITED ★ | $250.0K | 5 | 3 | $50.0K |
| 12 | R.S. SURGIPHARM PRIVATE LIMITED | $214.1K | 71 | 2 | $3.0K |
DR Reddy S Laboratories Limited ranks #8 among 196 Indian Bevacizumab exporters. Average shipment value of $50.0K compared to the market average of $77.5K. The closest competitors by value are MYLAN PHARMACEUTICALS PRIVATE LIMITED and DR REDDYS LABORATORIES LIMITED.
Which Indian Ports Ship Bevacizumab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 345 | 24.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 327 | 23.2% |
| HYDERABAD ACC (INHYD4) | 132 | 9.4% |
| Bombay Air | 89 | 6.3% |
| DELHI AIR CARGO ACC (INDEL4) | 48 | 3.4% |
| DELHI AIR | 47 | 3.3% |
| HYDERABAD AIR | 36 | 2.6% |
| AHEMDABAD AIR | 32 | 2.3% |
What Other Advanced Oncology Products Does DR Reddy S Laboratories Limited Export?
DR Reddy S Laboratories Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on DR Reddy S Laboratories Limited's Bevacizumab Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Dr. Reddy's. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, creating opportunities for Indian exporters. Dr. Reddy's, with its established presence and compliance with stringent regulatory standards, is well-positioned to capitalize on this shift.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement. Dr. Reddy's commitment to quality and regulatory adherence ensures its continued access to the EU market, despite the evolving regulatory landscape.
DR Reddy S Laboratories Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for Dr. Reddy's. The company has consistently adhered to FDA, WHO, and EU Good Manufacturing Practices (GMP), ensuring the quality and safety of its products. This commitment is crucial in sustaining trust and credibility in global markets.
However, regulatory challenges persist. In April 2025, Dr. Reddy's received a show cause notice from the Indian Income Tax Department concerning a proposed demand of over ₹2,395 crore related to the merger of Dr. Reddy's Holding Ltd with itself. The company has stated its belief that there is no tax liability arising from the merger and is addressing the matter through appropriate channels. (business-standard.com)
About DR Reddy S Laboratories Limited
DR Reddy S Laboratories Limited exports 50 products worth $310.6M. Beyond Bevacizumab, top products include Metoprolol, Omeprazole, Fexofenadine, Clopidogrel, Esomeprazole. View the complete DR Reddy S Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Bevacizumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Bevacizumab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: DR Reddy S Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 141 individual customs records matching DR Reddy S Laboratories Limited exporting Bevacizumab, covering 103 formulations to 15 countries via 26 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 100+ countries, 346+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Bevacizumab Export Data from DR Reddy S Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddy S Laboratories Limited's Bevacizumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddy S Laboratories Limited
Full Company Profile →
50 products · $310.6M total trade · 19 categories
Bevacizumab Stats
Company Overview
Top Products by DR Reddy S Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for DR Reddy S Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Bevacizumab. For current shipment-level data, contact TransData Nexus.